{"id":7728,"date":"2018-04-05T16:49:32","date_gmt":"2018-04-05T22:49:32","guid":{"rendered":"https:\/\/crism.ca\/?page_id=7728"},"modified":"2026-09-23T11:06:59","modified_gmt":"2026-09-23T17:06:59","slug":"section-56","status":"publish","type":"page","link":"https:\/\/crism.ca\/fr\/section-56\/","title":{"rendered":"Consultation sur l'Article 56"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"7728\" class=\"elementor elementor-7728\" wpc-filter-elementor-widget=\"1\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-107cdc03 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"107cdc03\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-612f433\" data-id=\"612f433\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1f1a3066 elementor-widget__width-initial elementor-widget-tablet__width-initial elementor-widget-mobile__width-inherit elementor-widget elementor-widget-heading\" data-id=\"1f1a3066\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Section 56 Consultation<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-4964f2f elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"4964f2f\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-a5a69e7\" data-id=\"a5a69e7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3395eaa5 elementor-widget__width-initial elementor-widget elementor-widget-image\" data-id=\"3395eaa5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp\" class=\"attachment-full size-full wp-image-14732\" alt=\"\" srcset=\"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp 1280w, https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada-300x169.webp 300w, https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada-768x432.webp 768w\" sizes=\"(max-width: 1280px) 100vw, 1280px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-3c5f403\" data-id=\"3c5f403\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-573710ba elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"573710ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div id=\"text-block-2\" class=\"mk-text-block jupiter-donut- \"><p>Health Canada commissioned the CRISM network to conduct a national consultation on the barriers to accessing treatment options for opioid use disorder. CRISM reached out to over 250 stakeholders via an online survey and teleconference meetings and submitted a report on the findings in December 2017.<\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4010d16 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"4010d16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The following research projects were rapidly established to explore how COVID-19 impacts people who use drugs (PWUD). The findings will help inform future research and guidance for healthcare professionals, service providers, and policymakers.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5168de59 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"5168de59\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm elementor-animation-grow\" href=\"https:\/\/crism.ca\/wp-content\/uploads\/2021\/06\/CRISM-Sec-56-Consultation-Report-submitted-Dec-21.pdf\" target=\"_blank\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Full Report (EN)<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-61f5e3f9 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"61f5e3f9\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7f310def\" data-id=\"7f310def\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-72e5e27 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"72e5e27\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div id=\"text-block-2\" class=\"mk-text-block jupiter-donut- \"><p>Methadone, a medication primarily used to treat chronic pain and opioid use disorder, is a controlled substance under the\u00a0<em>Controlled Drugs and Substances Act<\/em>\u00a0(CDSA), and activities with it are regulated under the\u00a0<em>Narcotic Control Regulations<\/em>\u00a0(NCR). The NCR required practitioners (e.g., physicians and nurse practitioners) to obtain an exemption under section 56(1) of the CDSA before they can prescribe, administer, sell or provide methadone.<a href=\"https:\/\/web.archive.org\/web\/20250117054032\/https:\/\/crism.ca\/projects\/s56\/#_ftnref1\" name=\"_ftn1\"><\/a><\/p><p>Experts from across Canada cited the section 56 exemption process as a barrier to care and recommended its removal,\u00a0while also recommending that strategies are in place to maintain appropriate training and monitoring for methadone treatment delivery.\u00a0 On March 21, 2018, Health Canada posted amendments to the NCR that will remove the section 56 requirement and allow licensed dealers and practitioners to provide or prescribe methadone similar to other opioid agonist treatments. The amendments also ease some restrictions on access to diacetylmorphine. These changes will come into effect on May 19, 2018.<\/p><div class=\"clearboth\">\u00a0<\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-23ded79 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"23ded79\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm elementor-animation-grow\" href=\"https:\/\/gazette.gc.ca\/rp-pr\/p2\/2018\/2018-03-21\/html\/sor-dors37-eng.html\" target=\"_blank\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Amendments to the NCR<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a5e27a6 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"a5e27a6\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-31448ac1\" data-id=\"31448ac1\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;gradient&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-2a97c48e elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"2a97c48e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-69f2917a\" data-id=\"69f2917a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d6e00c7 elementor-widget-divider--view-line_text elementor-widget-divider--element-align-left elementor-widget elementor-widget-divider\" data-id=\"d6e00c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_translateX_effect&quot;:&quot;yes&quot;,&quot;motion_fx_translateX_speed&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:1,&quot;sizes&quot;:[]},&quot;motion_fx_devices&quot;:[&quot;desktop&quot;],&quot;motion_fx_translateX_affectedRange&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:0,&quot;end&quot;:100}}}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t\t<span class=\"elementor-divider__text elementor-divider__element\">\n\t\t\t\tAdditional Materials\t\t\t\t<\/span>\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-6539389b elementor-widget elementor-widget-spacer\" data-id=\"6539389b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-29a8fa56 elementor-widget elementor-widget-text-editor\" data-id=\"29a8fa56\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/news\/2018\/03\/the-honourable-ginette-petitpas-taylor-minister-of-health-announces-new-measures-to-reduce-barriers-to-treatment-and-231-m-to-address-the-o.html\">Health Canada news release<\/a><\/li><li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/news\/2018\/03\/reducing-regulatory-barriers-to-accessing-treatment-and-new-funding-for-innovative-projects.html\">Health Canada backgrounder on new regulations and activities to address the opioid crisis<\/a><\/li><li><a href=\"https:\/\/www.theglobeandmail.com\/canada\/article-feds-ease-restrictions-on-prescription-heroin-to-address-opioid-2\/\">News article in the Globe and Mail<\/a><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Section 56 Consultation Health Canada commissioned the CRISM network to conduct a national consultation on the barriers to accessing treatment options for opioid use disorder. CRISM reached out to over 250 stakeholders via an online survey and teleconference meetings and submitted a report on the findings in December 2017. The following research projects were rapidly established to explore how COVID-19 impacts people who use drugs (PWUD). The findings will help inform future research and guidance for healthcare professionals, service providers, and policymakers. Full Report (EN) Methadone, a medication primarily used to treat chronic pain and opioid use disorder, is a controlled substance under the\u00a0Controlled Drugs and Substances Act\u00a0(CDSA), and activities with it are regulated under the\u00a0Narcotic Control Regulations\u00a0(NCR). The NCR required practitioners (e.g., physicians and nurse practitioners) to obtain an exemption under section 56(1) of the CDSA before they can prescribe, administer, sell or provide methadone. Experts from across Canada cited the section 56 exemption process as a barrier to care and recommended its removal,\u00a0while also recommending that strategies are in place to maintain appropriate training and monitoring for methadone treatment delivery.\u00a0 On March 21, 2018, Health Canada posted amendments to the NCR that will remove the section 56 requirement and allow licensed dealers and practitioners to provide or prescribe methadone similar to other opioid agonist treatments. The amendments also ease some restrictions on access to diacetylmorphine. These changes will come into effect on May 19, 2018. \u00a0 Amendments to the NCR Additional Materials Health Canada news release Health Canada backgrounder on new regulations and activities to address the opioid crisis News article in the Globe and Mail<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"footnotes":"","_members_access_role":[],"_members_access_error":"","_links_to":"","_links_to_target":""},"folder":[],"wf_page_folders":[365],"class_list":["post-7728","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Section 56 Consultation - CRISM<\/title>\n<meta name=\"description\" content=\"CRISM analysis of Section 56 CDSA exemptions and their impact on opioid use disorder treatment access, policy, and regulatory barriers in Canada.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/crism.ca\/fr\/section-56\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Section 56 Consultation - CRISM\" \/>\n<meta property=\"og:description\" content=\"CRISM analysis of Section 56 CDSA exemptions and their impact on opioid use disorder treatment access, policy, and regulatory barriers in Canada.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/crism.ca\/fr\/section-56\/\" \/>\n<meta property=\"og:site_name\" content=\"CRISM\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T17:06:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/\",\"url\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/\",\"name\":\"Section 56 Consultation - CRISM\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/crism.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/crism.ca\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Health-Canada.webp\",\"datePublished\":\"2018-04-05T22:49:32+00:00\",\"dateModified\":\"2026-09-23T17:06:59+00:00\",\"description\":\"CRISM analysis of Section 56 CDSA exemptions and their impact on opioid use disorder treatment access, policy, and regulatory barriers in Canada.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/crism.ca\\\/section-56\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/#primaryimage\",\"url\":\"https:\\\/\\\/crism.ca\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Health-Canada.webp\",\"contentUrl\":\"https:\\\/\\\/crism.ca\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Health-Canada.webp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/crism.ca\\\/section-56\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/crism.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Section 56 Consultation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/crism.ca\\\/#website\",\"url\":\"https:\\\/\\\/crism.ca\\\/\",\"name\":\"CRISM\",\"description\":\"Canadian Research Initiative in Substance Matters\",\"publisher\":{\"@id\":\"https:\\\/\\\/crism.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/crism.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/crism.ca\\\/#organization\",\"name\":\"Canadian Research Initiative in Substance Matters\",\"url\":\"https:\\\/\\\/crism.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/crism.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/crism.ca\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/crism_long_en.png\",\"contentUrl\":\"https:\\\/\\\/crism.ca\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/crism_long_en.png\",\"width\":1127,\"height\":315,\"caption\":\"Canadian Research Initiative in Substance Matters\"},\"image\":{\"@id\":\"https:\\\/\\\/crism.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/crism-icris\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Section 56 Consultation - CRISM","description":"CRISM analysis of Section 56 CDSA exemptions and their impact on opioid use disorder treatment access, policy, and regulatory barriers in Canada.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/crism.ca\/fr\/section-56\/","og_locale":"fr_CA","og_type":"article","og_title":"Section 56 Consultation - CRISM","og_description":"CRISM analysis of Section 56 CDSA exemptions and their impact on opioid use disorder treatment access, policy, and regulatory barriers in Canada.","og_url":"https:\/\/crism.ca\/fr\/section-56\/","og_site_name":"CRISM","article_modified_time":"2026-09-23T17:06:59+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/crism.ca\/section-56\/","url":"https:\/\/crism.ca\/section-56\/","name":"Section 56 Consultation - CRISM","isPartOf":{"@id":"https:\/\/crism.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/crism.ca\/section-56\/#primaryimage"},"image":{"@id":"https:\/\/crism.ca\/section-56\/#primaryimage"},"thumbnailUrl":"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp","datePublished":"2018-04-05T22:49:32+00:00","dateModified":"2026-09-23T17:06:59+00:00","description":"CRISM analysis of Section 56 CDSA exemptions and their impact on opioid use disorder treatment access, policy, and regulatory barriers in Canada.","breadcrumb":{"@id":"https:\/\/crism.ca\/section-56\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/crism.ca\/section-56\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/crism.ca\/section-56\/#primaryimage","url":"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp","contentUrl":"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/Health-Canada.webp"},{"@type":"BreadcrumbList","@id":"https:\/\/crism.ca\/section-56\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/crism.ca\/"},{"@type":"ListItem","position":2,"name":"Section 56 Consultation"}]},{"@type":"WebSite","@id":"https:\/\/crism.ca\/#website","url":"https:\/\/crism.ca\/","name":"CRISM","description":"Canadian Research Initiative in Substance Matters","publisher":{"@id":"https:\/\/crism.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/crism.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/crism.ca\/#organization","name":"Canadian Research Initiative in Substance Matters","url":"https:\/\/crism.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/crism.ca\/#\/schema\/logo\/image\/","url":"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/crism_long_en.png","contentUrl":"https:\/\/crism.ca\/wp-content\/uploads\/2025\/08\/crism_long_en.png","width":1127,"height":315,"caption":"Canadian Research Initiative in Substance Matters"},"image":{"@id":"https:\/\/crism.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/crism-icris"]}]}},"_links":{"self":[{"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/pages\/7728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/comments?post=7728"}],"version-history":[{"count":22,"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/pages\/7728\/revisions"}],"predecessor-version":[{"id":25575,"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/pages\/7728\/revisions\/25575"}],"wp:attachment":[{"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/media?parent=7728"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/folder?post=7728"},{"taxonomy":"wf_page_folders","embeddable":true,"href":"https:\/\/crism.ca\/fr\/wp-json\/wp\/v2\/wf_page_folders?post=7728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}